Ira Jacobs

12.7k total citations · 3 hit papers
232 papers, 9.5k citations indexed

About

Ira Jacobs is a scholar working on Orthopedics and Sports Medicine, Cell Biology and Complementary and alternative medicine. According to data from OpenAlex, Ira Jacobs has authored 232 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Orthopedics and Sports Medicine, 62 papers in Cell Biology and 59 papers in Complementary and alternative medicine. Recurrent topics in Ira Jacobs's work include Sports Performance and Training (66 papers), Muscle metabolism and nutrition (62 papers) and Cardiovascular and exercise physiology (59 papers). Ira Jacobs is often cited by papers focused on Sports Performance and Training (66 papers), Muscle metabolism and nutrition (62 papers) and Cardiovascular and exercise physiology (59 papers). Ira Jacobs collaborates with scholars based in United States, Canada and Sweden. Ira Jacobs's co-authors include B. Sjödin, Douglas G. Bell, J. Karlsson, Peter Kaiser, Tom M. McLellan, B. Noble, Ruggero Ceci, Gunnar Borg, Peter Tikuisis and D. G. Bell and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Ira Jacobs

227 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A category-ratio perceived exertion scale

1983 511 citations Ira Jacobs et al. profile →
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

2013 430 citations Sant P. Chawla, Edwin Choy et al. profile →
Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

2012 332 citations Daniel Branstetter, Scott D. Nelson et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Ira Jacobs

Since Specialization

Citations

This map shows the geographic impact of Ira Jacobs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ira Jacobs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ira Jacobs more than expected).

Fields of papers citing papers by Ira Jacobs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ira Jacobs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ira Jacobs. The network helps show where Ira Jacobs may publish in the future.

Co-authorship network of co-authors of Ira Jacobs

This figure shows the co-authorship network connecting the top 25 collaborators of Ira Jacobs. A scholar is included among the top collaborators of Ira Jacobs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ira Jacobs. Ira Jacobs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design 2024 ·Journal of Cachexia Sarcopenia and Muscle ·John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon L. Lubaczewski, Danna M. Breen, Magdalena Harrington, Ira Jacobs, Ruolun Qiu, James H. Revkin, Michelle I. Rossulek, Aditi R. Saxena	20
2	Potential physiological responses contributing to the ergogenic effects of acute ischemic preconditioning during exercise: A narrative review 2022 ·Frontiers in Physiology ·(unknown), Ira Jacobs	11
3	The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials 2021 ·Oncology ·Robert L. Coleman, J. Thaddeus Beck, Joaquina Baranda, Ira Jacobs, Karen E. Smoyer, Lauren J. Lee, (unknown), Justin M. McGinnis, Apar Kishor Ganti	19
4	<p>Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews</p> 2020 ·ClinicoEconomics and Outcomes Research ·Lauren J. Lee, C.S. Kwon, Anna Forsythe, Carla Mamolo, Elizabeth T. Masters, Ira Jacobs	32
5	Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers? 2017 ·PubMed ·Bradley J. Monk, Warner K. Huh, (unknown), Ira Jacobs	4
6	Rate dependent influence of arterial desaturation on self-selected exercise intensity during cycling 2017 ·PLoS ONE ·(unknown), Stephen S. Cheung, Scott Thomas, Ira Jacobs	4
7	Biosimilars and cancer treatment of older patients 2016 ·Journal of Geriatric Oncology ·Stuart M. Lichtman, Thomas Reske, Ira Jacobs	1
8	Clamping end-tidal carbon dioxide during graded exercise with control of inspired oxygen 2016 ·Respiratory Physiology & Neurobiology ·(unknown), (unknown), James Duffin, Greg D. Wells, Ira Jacobs	4
9	Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence 2016 ·BioDrugs ·Ira Jacobs, Danielle Petersel, (unknown), (unknown), Carol F. Kirchhoff, Gregory L. Finch, Sadiq Lula	36
10	Regulatory considerations in oncologic biosimilar drug development 2015 ·mAbs ·(unknown), Helen B. Hartman, Ira Jacobs	20
11	Clinical considerations for the development of biosimilars in oncology 2015 ·mAbs ·Mark A. Socinski, Giuseppe Curigliano, Ira Jacobs, Barry Gumbiner, (unknown), (unknown)	46
12	Biosimilar Safety Considerations in Clinical Practice 2013 ·Seminars in Oncology ·Edwin Choy, Ira Jacobs	19
13	Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone breakdown → 2012 ·Clinical Cancer Research ·Daniel Branstetter, Scott D. Nelson, J. Carlos Manivel, Jean‐Yves Blay, Sant P. Chawla, David M. Thomas, Susie Jun, Ira Jacobs	332
14	Role of Sentinel Lymph Node Biopsy in Patients With Thin (<1 mm) Primary Melanoma 2003 ·Annals of Surgical Oncology ·Ira Jacobs, Chen‐Kang Chang, Tapas K. Das Gupta, George I. Salti	46
15	Effects of caffeine, ephedrine and their combination on time to exhaustion during high-intensity exercise 1998 ·European Journal of Applied Physiology ·Douglas G. Bell, Ira Jacobs, J. Zámečník	76
16	Effect of Upper Respiratory Tract Infection in Patients with Neuromuscular Disease 1997 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), Ira Jacobs, Gerald S. Supinski, Anthony F. DiMarco	81
17	Diet and Muscle Glycogen Concentration in Relation to Physical Performance in Swedish Elite Ice Hockey Players 1996 ·International Journal of Sport Nutrition ·Christian Åkermark, Ira Jacobs, (unknown), J. Karlsson	39
18	Rates of energy substrates utilization during human cold exposure 1989 ·European Journal of Applied Physiology ·Robert J. Vallerand, Ira Jacobs	66
19	Acute altitude exposure and altered acid-base states 1988 ·European Journal of Applied Physiology ·T. M. McLellan, Ira Jacobs, (unknown)	28
20	Relevance of Muscle Fibre Type to Fatigue in Short Intense and Prolonged Exercise in Man 1981 ·Novartis Foundation symposium ·J. Karlsson, Bertil Sjödin, Ira Jacobs, Peter Kaiser	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact